Therapeutic delivery · 2025
PEGylated MXene@AgNP nanocomposite for targeted release of docetaxel to breast carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mishra Pavni, Yadav Pooja, Chourasia Manish K, Dave Vivek
Аннотация
AIM: MXene pertains to the family of two-dimensional materials with excellent surface area, biocompatibility, and many possibilities for surface functionalization. Owing to this, a multifunctional MXene nanocomposite was developed for targeted drug delivery at tumor site as current treatment regimens show increased adverse effects and limited selectivity.
METHOD: MAX phase titanium aluminum carbide (Ti3AlC2) was synthesized, which serves as the precursor for the production of Ti3C2TX MXene. Additionally, green-synthesized silver nanoparticles (AgNP) were affixed onto the MXene's surface, forming the MXene@AgNP nanocomposite. This nanocomposite was further employed as a drug delivery carrier to deliver chemotherapeutic drug, docetaxel (DTX), linked covalently to the MXene@AgNP via polyethylene glycol (PEG), resulting in the final composition of MXene@AgNP@PEG@DTX.
RESULT: The final nanocomposite exhibits both thermal and pH-responsive in vitro drug delivery capabilities, with maximum drug release of 60% at pH 5.4 after 48 hours. The IC50 value for final nanocomposite was determined at 2.698 µg/mL, significantly lower than IC50 value 9.630 µg/mL for DTX against breast carcinoma. Enhanced cellular uptake of the MXene@AgNP carrier was confirmed through cellular uptake studies.
CONCLUSION: This work broadens the scope for therapeutic approach toward cancer through the development of nanocomposite by providing a potent and biocompatible alternative.
METHOD: MAX phase titanium aluminum carbide (Ti3AlC2) was synthesized, which serves as the precursor for the production of Ti3C2TX MXene. Additionally, green-synthesized silver nanoparticles (AgNP) were affixed onto the MXene's surface, forming the MXene@AgNP nanocomposite. This nanocomposite was further employed as a drug delivery carrier to deliver chemotherapeutic drug, docetaxel (DTX), linked covalently to the MXene@AgNP via polyethylene glycol (PEG), resulting in the final composition of MXene@AgNP@PEG@DTX.
RESULT: The final nanocomposite exhibits both thermal and pH-responsive in vitro drug delivery capabilities, with maximum drug release of 60% at pH 5.4 after 48 hours. The IC50 value for final nanocomposite was determined at 2.698 µg/mL, significantly lower than IC50 value 9.630 µg/mL for DTX against breast carcinoma. Enhanced cellular uptake of the MXene@AgNP carrier was confirmed through cellular uptake studies.
CONCLUSION: This work broadens the scope for therapeutic approach toward cancer through the development of nanocomposite by providing a potent and biocompatible alternative.